As chair of the ACR Journal Publications Committee, Dr. Tsao brings extensive experience with journals and many ideas about how to improve the submission and review process.
A ‘Polarized’ Topic: Synovial Fluid Crystal Examinations
Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
State Legislative Update, Spring 2025
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
CMS Nominee Mehmet Oz’s Stated Policy Priorities & Rheumatology
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
ACR Commends the Introduction of Legislation to Support the Medical Workforce
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
March Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working on behalf of ACR members to address underwater formulary requirements for biosimilars, mandated switches to biosimilars, evaluation and management downcoding and more.
HHS Policy Shift Raises Questions about Future of Public Comment on Rulemaking
The rescindment of the Richardson Waiver in late February suggests that the HHS may move toward rulemaking without providing public notice and comment procedures.
How NIH, FDA Nominees May Affect Rheumatology
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
Flares Rare After COVID Vaccination
The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…
2025 Advocates for Arthritis Applications Now Open
This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 325
- Next Page »